Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway

Journal of Geriatric Cardiology

Volumn 12, Issue 4, 2015, Pages 410-416

  Wang, Yan Gui ^a,b   Yang, Tian Lun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

AMPK SREBP1 pathway; Fatty degeneration; Foam cell; Liraglutide; Oxidative stress

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIRAGLUTIDE; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEGENERATION; DISORDERS OF LIPID METABOLISM; DRUG MECHANISM; FATTY DEGENERATION; FOAM CELL; LIPID STORAGE; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84939518498     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.11909/j.issn.1671-5411.2015.04.013     Document Type: Article

References (32)

1. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996; 93: 34-41.
2. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14: 177-192.
3. Vigen C, Hodis HN, Selzer RH, et al. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study). Am J Cardiol 2005; 95: 1277-1282.
4. Wajcberg E, Amarah A. Liraglutide in the management of type 2 diabetes. Drug Des Devel Ther 2010; 4: 279-290.
5. Gaspari T, Welungoda I, Widdop RE, et al. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diab Vasc Dis Res 2013; 10: 353-360.
6. Ronnebaum SM, Patterson C, Schisler JC. Minireview: hey U(PS): metabolic and proteolytic homeostasis linked via AMPK and the ubiquitin proteasome system. Mol Endocrinol 2014; 28: 1602-1615.
7. Li D, Wang D, Wang Y, et al. Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem 2010; 285: 33499-33509.
8. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996; 7: 330-335.
9. Vazquez G. TRPC channels as prospective targets in atherosclerosis: terra incognita. Front Biosci (Schol Ed) 2012; 4: 157-166.
10. Kataoka H, Kume N, Miyamoto S, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999; 99: 3110-3117.
11. Miller YI, Choi SH, Fang L, et al. Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell Biochem 2010; 51: 229-251.
12. Endemann G, Stanton LW, Maden KS, et al. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993; 268: 11811-11816.
13. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386: 292-296.
14. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
15. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-20966.
16. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116: 1832-1844.
17. Greaves DR, Gordon S. Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res 2005; 46: 11-20.
18. Schmitz G, Grandl M. Endolysosomal phospholipidosis and cytosolic lipid droplet storage and release in macrophages. Biochim Biophys Acta 2009; 1791: 524-539.
19. Yancey PG, Jerome WG. Lysosomal cholesterol derived from mildly oxidized low density lipoprotein is resistant to efflux. J Lipid Res 2001; 42: 317-327.
20. Yancey PG, Miles S, Schwegel J, et al. Uptake and trafficking of mildly oxidized LDL and acetylated LDL in THP-1 cells does not explain the differences in lysosomal metabolism of these two lipoproteins. Microsc Microanal 2002; 8: 81-93.
21. Dhaliwal BS, Steinbrecher UP. Cholesterol delivered to macrophages by oxidized low density lipoprotein is sequestered in lysosomes and fails to efflux normally. J Lipid Res 2000; 41: 1658-1665.
22. Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull 2003; 26: 1-9.
23. Zhou SW, Zhang M, Zhu M. Liraglutide reduces lipid accumulation in steatotic L-02 cells by enhancing autophagy. Mol Med Rep 2014; 10: 2351-2357.
24. Gao H, Xu L, Li D, et al. Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-? and TGF-?1 in rats with non-alcoholic fatty liver disease. Nan Fang Yi Ke Da Xue Xue Bao 2013; 33: 1661-1664 (In Chinese).
25. Zampetaki A, Dudek K, Mayr M. Oxidative stress in atherosclerosis: the role of microRNAs in arterial remodeling. Free Radic Biol Med 2013; 64: 69-77.
26. Hardie DG. The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 2004; 117: 5479-5487.
27. Cheung PC, Salt IP, Davies SP, et al. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 2000; 346: 659-669.
28. Hardie DG. AMP-activated protein kinase: a master switch in glucose and lipid metabolism. Rev Endocr Metab Disord 2004; 5: 119-125.
29. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002; 30: 1064-1070.
30. Bronner M, Hertz R, Bar-Tana J. Kinase-independent transcriptional co-activation of peroxisome proliferator-activated receptor alpha by AMP-activated protein kinase. Biochem J 2004; 384: 295-305.
31. Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metabolism 2011; 13: 376-388.
32. Kawaguchi T, Osatomi K, Yamashita H, et al. Mechanism for fatty acid sparing effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 2000; 277: 3829-3835.